2025年12月名古屋に集結！俳優たちの熱き戦いが再び！ 2025年12月、名古屋で俳優たちが集結するエンターテインメントショー「Rdy？Vol.2 - vs Games -」が開催されます。熱戦が繰り広げられます！

2025年12月名古屋に集結！俳優たちの熱き戦いが再び！ #名古屋 #ACTORS☆LEAGUE #Rdy

2025年12月、名古屋で俳優たちが集結するエンターテインメントショー「Rdy？Vol.2 - vs Games -」が開催されます。熱戦が繰り広げられます！

名古屋で再び開催決定！Rdy？Vol.2が熱狂の2日間を演出 2025年12月27日、28日の2日間、名古屋でRdy？Vol.2が開催されます。豪華俳優陣が集結し、熱戦とパフォーマンスをお届け！

名古屋で再び開催決定！Rdy？Vol.2が熱狂の2日間を演出 #Rdy #ACTORS☆LEAGUE #高野洸

2025年12月27日、28日の2日間、名古屋でRdy？Vol.2が開催されます。豪華俳優陣が集結し、熱戦とパフォーマンスをお届け！

名古屋で熱狂のライブイベント『Rdy？Vol.2 - vs Games -』開催！ 2025年12月、名古屋で人気俳優たちが集結するライブエンターテインメント『Rdy？Vol.2 - vs Games -』が開催決定。新たな熱戦が繰り広げられる！

名古屋で熱狂のライブイベント『Rdy？Vol.2 - vs Games -』開催！ #愛知県 #名古屋市 #東海エリア #ACTORS☆LEAGUE #Rdy

2025年12月、名古屋で人気俳優たちが集結するライブエンターテインメント『Rdy？Vol.2 - vs Games -』が開催決定。新たな熱戦が繰り広げられる！

Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025 Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation and Proximity Inducer Platform at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held at the...

#RDY Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025

www.stocktitan.net/news/RDY/aurigene-oncolo...

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Coya Therapeutics (NASDAQ:COYA) has received FDA acceptance of its Investigational New Drug (IND) application for COYA 302, a proprietary immunomodulatory biologic combination therapy for treating Amyotrophic Lateral Sclerosis (ALS). The acceptance enables the company to proceed with a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the treatment's efficacy and safety.The milestone triggers a $4.2 million payment to Coya from its partner Dr. Reddy's Laboratories (DRL). The development represents a significant step in Coya's partnership with DRL to advance potential treatments for ALS patients.

#COYA #RDY Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

www.stocktitan.net/news/COYA/coya-therapeut...

Dr. Reddy’s Q1FY26 Financial Results Dr. Reddy's Laboratories (NYSE:RDY) reported Q1 FY26 financial results with revenues of ₹85,452 Mn, showing an 11% year-over-year growth. The company's gross margin stood at 56.9%, down from 60.4% in Q1FY25. Key highlights include:The Global Generics segment revenue grew 10% YoY to ₹75,620 Mn, while North America revenues declined 11% YoY due to increased price erosion in products like Lenalidomide. European operations saw significant growth of 142% YoY, largely driven by the acquired Nicotine Replacement Therapy portfolio.Notable developments include expanded partnerships with Alvotech for biosimilar pembrolizumab and Sanofi for BeyfortusTM launch in India. The company maintained strong financial health with ₹73,169 Mn in cash and investments and achieved an improved 'A' rating in CDP's Climate category.

#RDY Dr. Reddy’s Q1FY26 Financial Results

www.stocktitan.net/news/RDY/dr-reddy-s-q1fy...

Dr. Reddy’s Q4 & Full Year FY25 Financial Results Dr. Reddy's Laboratories (NYSE: RDY) reported strong Q4 FY25 financial results with revenues of ₹85,060 Mn, up 20% YoY. The company achieved double-digit growth across businesses, with net profit rising 22% YoY to ₹15,939 Mn. Key highlights include: • Global Generics revenue grew 23% YoY to ₹75,365 Mn • North America revenue increased 9% YoY to ₹35,586 Mn • European revenue surged 145% YoY to ₹12,750 Mn, boosted by NRT business • India revenue grew 16% YoY to ₹13,047 Mn • EBITDA margin improved to 29.1% The growth was driven by successful product launches, increased revenues from key U.S. products, and integration of the acquired NRT business. The company launched 7 new products in the U.S. and has 76 generic filings pending FDA approval.

#RDY Dr. Reddy’s Q4 & Full Year FY25 Financial Results

www.stocktitan.net/news/RDY/dr-reddy-s-q4-f...

Mandatory vs Voluntary Evacuation

Mandatory: you are being ordered out of the area. Dangerous conditions will exist, preventing first responders from responding to calls during the emergency.

Voluntary: it is being suggested to leave the area. Dangerous conditions may exist in the area soon. #rdy

Portion of poster showing Yale School Of Management list of 213 “Grade F” companies that are still doing business with the Russian Federation (as of February 27th, 2025) (Diesel S.p.A. through Duol). Subject to updates, corrections and revisions.

👆 see above for full poster

Branch🧵 16/

#StandWithUkraine

Closer view of #GradeF / #DiggingInList companies…

#Diesel
#OTBGroup, a/k/a #OnlyTheBrave, S.p.A.

#Dinex

#Doka
#Umdasch Group AG

#DrReddys
#RDY
#DRREDDY

#Duol

#YaleCeliList: som.yale.edu/story/2022/o...

#Russia is #BrandUnsafe

slept on studio addict so crazy, def posed to be at least top 10. tmblr music bouta be even crazier #rdy

FDA Green Lights Review of New Prolia Biosimilar: Major Win for Dr. Reddy's Cancer Treatment Pipeline FDA accepts BLA for denosumab biosimilar targeting osteoporosis and cancer bone complications. Partnership combines Alvotech's manufacturing with Dr. Reddy's commercialization expertise.

#RDY #ALVO Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

www.stocktitan.net/news/RDY/alvotech-and-dr...

Logo and company information for Dr. Reddy’s Laboratories Ltd. (Hyderabad, India).

Wikipedia article and company website information for Dr. Reddy’s Laboratories Ltd. (Hyderabad, India).

Screenshot of Yale CELI List information pertaining to Dr. Reddy’s Laboratories Ltd. (Hyderabad, India).

Poster showing Yale School Of Management list of “Grade F” companies that are still doing business with the Russian Federation (as of November 28th, 2024).

🧵 65/
#StandWithUkraine
#YaleCELIList

Plz ask #GradeF / #DiggingInList Companies to stop doing business with the #RussianFederation / #RF

e.g.:
#DrReddys Laboratories Ltd
#Hyderabad, #India, #IND
www.drreddys.com/contact-us

#NYSE: #RDY
#BSE: 600124
#NSE: #DRREDDY
#NIFTY50

#Russia is #BrandUnsafe

Major Biosimilar Deal: Dr. Reddy's Secures Exclusive U.S. & EU Rights for Multiple Myeloma Treatment Dr. Reddy's gains exclusive U.S. and European rights to HLX15, a Darzalex biosimilar, through $131.6M deal with Henlius. Expands oncology portfolio with multiple myeloma treatment.

#RDY Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

www.stocktitan.net/news/RDY/dr-reddy-s-ente...

Major Biosimilar Licensing Deal: Henlius Secures $165M Agreement for Cancer Drug Rights Henlius partners with Dr. Reddy's, receiving $33M upfront plus $131.6M in potential milestones for HLX15 daratumumab biosimilar rights across US and European markets.

#RDY Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

www.stocktitan.net/news/RDY/henlius-and-dr-...

Dr. Reddy's Q3 Revenue Surges 16% as NRT Acquisition Powers European Sales Growth of 143% Dr. Reddy's Laboratories reports robust Q3FY25 with ₹83,586 Mn revenue, boosted by NRT business integration. Europe leads growth while maintaining 58.7% gross margin.

#RDY Dr. Reddy’s Q3 & 9MFY25 Financial Results

www.stocktitan.net/news/RDY/dr-reddy-s-q3-9...

Market Momentum: Your Weekly Financial Forecast & Market Prep Issue 28 / What to expect Jan 13, 2025 thru Jan 17, 2025

The latest VL newsletter is out! All VL software subs get it included with their sub at no additional cost. Tickers discussed include: #SPY #QQQ #IWM #DIA #FVRR #HDB #RDY #VV #RGTI #SAP

Enjoy.
volumeleaders.substack.com/p/market-mom...

Dr. Reddy's Launches Breakthrough Cancer Drug Toripalimab in India, Shows 48% Risk Reduction | RDY Stock News Dr. Reddy's introduces Zytorvi, a groundbreaking immuno-oncology treatment for nasopharyngeal carcinoma. First approved therapy shows 48% reduced risk when combined with chemotherapy.

#RDY Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

#news #stocks #investing

www.stocktitan.net/news/RDY/dr-reddy-s-laun...

#RDY Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

www.stocktitan.net/news/RDY/dr-reddy-s-labo...